Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With AspirinThe Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study
Martine Gilard, MD*,*,
Bertrand Arnaud, PharmD ,
Jean-Christophe Cornily, MD*,
Grégoire Le Gal, MD ,
Karine Lacut, MD ,
Geneviève Le Calvez, PharmD,
Jacques Mansourati, MD*,
Dominique Mottier, MD,
Jean-François Abgrall, MD,1 and
Jacques Boschat, MD*,1
* Department of Cardiology, Brest University Hospital, Brest, France
Department of Hematology, INSERM 0502, Brest University Hospital, Brest, France
Center for Clinical Investigation, EA3878, Brest University Hospital, Brest, France
Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Consort Statement and Flow Diagram
From 354 eligible patients, 140 were included. Finally, 64 patients were analyzed in the omeprazole group and 60 in the placebo group. PPI = proton pump inhibitor.
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Mean PRI on Days 1 and 7 in the Two Groups
On Day 1, mean platelet reactivity index (PRI) was 83.2% and 83.9%, respectively, in the placebo and omeprazole groups (nonsignificant). On Day 7, mean PRI was 39.8% and 51.4%, respectively, in the placebo and omeprazole groups (p < 0.0001). VASP = vasodilator-stimulated phosphoprotein.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Variation of Platelet Reactivity Index
The platelet reactivity index (PRI) decrease was –43.3% in the placebo group and –32.6% in the omeprazole group after 7 days of treatment (p < 0.0001).
|
|
|
